Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 26
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Redhill Biopharma Ltd
RDHL
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.4151
-0.0081
-1.91%
Dern. MÀJ: Oct 23, 4:52 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
Redhill Biopharma Financials
Redhill Biopharma (RDHL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Redhill Biopharma H1 2026 EPS $0.00 And Revenue $0.00
Redhill Biopharma (NASDAQ:RDHL) reported H1 2026 EPS $0.00 And Revenue $0.00.
Benzinga Newsdesk
PRO
Redhill Biopharma FY EPS $0.00, Sales $286.000K Down From $8.043M YoY
Redhill Biopharma (NASDAQ:RDHL) reported quarterly earnings of $0.00 per share. The company reported $286.000 thousand in sales this quarter. This is a 96.44 percent decrease over sales of $8.043 million the same period
Benzinga Newsdesk
PRO
Redhill Biopharma H1 Sales $4.079M Up From $2.572M YoY
Redhill Biopharma (NASDAQ:RDHL) reported $4.079 million in sales this quarter. This is a 58.59 percent increase over sales of $2.572 million the same period last year.
Benzinga Newsdesk
PRO
Redhill Biopharma FY 2024 EPS $(0.00) Down From $0.01 YoY, Sales $8.04M Up From $6.53M YoY
Redhill Biopharma (NASDAQ:RDHL) reported quarterly losses of $(0.02) per share. This is a 300 percent decrease over earnings of $0.01 per share from the same period last year. The company reported $8.04 million in sales
Benzinga Newsdesk
PRO
Redhill Biopharma H1 EPS $(0.00) Down From $0.04 YoY, Sales $2.57M Down From $5.39M YoY
Benzinga Newsdesk
Crude Oil Moves Lower; Moderna Shares Plunge
Avi Kapoor
